相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L
Shinya Sakata et al.
CANCER SCIENCE (2022)
Molecular analysis of ascitic fluid cytology reflects genetic changes of malignancies of the ovary equivalent to surgically resected specimens
Takahiro Nozaki et al.
CANCER CYTOPATHOLOGY (2022)
Detection of actionable mutations in cytological specimens obtained by endoscopic ultrasound-guided fine needle aspiration with rapid onsite evaluation in pancreatic cancer
Hiroshi Ohyama et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2022)
Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer
Tadashi Sakaguchi et al.
THORACIC CANCER (2021)
The Japanese Society of Pathology Practical Guidelines on the handling of pathological tissue samples for cancer genomic medicine
Yutaka Hatanaka et al.
PATHOLOGY INTERNATIONAL (2021)
Suitability of Bronchoscopic Biopsy Tissue Samples for Next-Generation Sequencing
Shuji Murakami et al.
DIAGNOSTICS (2021)
Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer
Kenji Amemiya et al.
CANCER CYTOPATHOLOGY (2021)
A method to improve genetic analysis of lung cancer samples
Tadashi Sakaguchi et al.
RESPIROLOGY (2021)
Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients
Yuki Takeyasu et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2021)
Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples
Daiji Nemoto et al.
THORACIC CANCER (2021)
Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer
Kei Kunimasa et al.
CANCER MEDICINE (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Relationship between formalin reagent and success rate of targeted sequencing analysis using formalin fixed paraffin embedded tissues
Kenji Amemiya et al.
CLINICA CHIMICA ACTA (2019)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh et al.
LANCET RESPIRATORY MEDICINE (2017)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Lung Cancer: Epidemiology, Etiology, and Prevention
Charles S. Dela Cruz et al.
CLINICS IN CHEST MEDICINE (2011)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2008)